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Abstract
Purpose: Acuros XB (AXB) dose calculation algorithm is available for external beam photon dose calculations in Eclipse treat-
ment planning system (TPS). The AXB can report the absorbed dose in two modes: dose-to-water (Dw) and dose-to-medium
(Dm). The main purpose of this study was to compare the dosimetric results of the AXB_Dm with that of AXB_Dw on real patient
treatment plans. Methods: Four groups of patients (prostate cancer, stereotactic body radiation therapy (SBRT) lung cancer, left
breast cancer, and right breast cancer) were selected for this study, and each group consisted of 5 cases. The treatment plans of
all cases were generated in the Eclipse TPS. For each case, treatment plans were computed using AXB_Dw and AXB_Dm for
identical beam arrangements. Dosimetric evaluation was done by comparing various dosimetric parameters in the AXB_Dw
plans with that of AXB_Dm plans for the corresponding patient case. Results: For the prostate cancer, the mean planning target
volume (PTV) dose in the AXB_Dw plans was higher by up to 1.0%, but the mean PTV dose was within ±0.3% for the SBRT
lung cancer. The analysis of organs at risk (OAR) results in the prostate cancer showed that AXB_Dw plans consistently pro-
duced higher values for the bladder and femoral heads but not for the rectum. In the case of SBRT lung cancer, a clear trend
was seen for the heart mean dose and spinal cord maximum dose, with AXB_Dw plans producing higher values than the
AXB_Dm plans. However, the difference in the lung doses between the AXB_Dm and AXB_Dw plans did not always produce a
clear trend, with difference ranged from -1.4% to 2.9%. For both the left and right breast cancer, the AXB_Dm plans produced
higher maximum dose to the PTV for all cases. The evaluation of the maximum dose to the skin showed higher values in the
AXB_Dm plans for all 5 left breast cancer cases, whereas only 2 cases had higher maximum dose to the skin in the AXB_Dm plans
for the right breast cancer. Conclusion: The preliminary dosimetric results from our clinical study showed that the selection of
either Dm or Dw in AXB is less likely to produce significant dosimetric differences in the clinical environment. However, the
difference between the AXB_Dm and AXB_Dw calculations depends on the disease site, and even for the same type of disease
(e.g., lung cancer), the results are patient specific.
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Introduction
In conventional radiation therapy treatment planning sys-
tems (TPS), photon dose calculation algorithms typically
report the absorbed dose as dose-to-water (Dw). Dose calcu-
lation algorithms employed in the TPS aim to best match the
computed results with the measurements, which are per-
formed in water phantoms. In recent years, there has been
significant interest in using dose calculation algorithms that
are based on Monte Carlo (MC) approach, which can report
the absorbed dose in dose-to-medium (Dm) mode. In the Dm
mode, the absorbed dose is computed to the medium con-
tained in the dose voxel of the material. Siebers et al.1 sug-
gested that the conversion of Dm to Dw may be desirable in
some of the situations when MC-based calculations are used
in external beam photon radiation therapy. Currently, dosi-
metric calibration protocols of external beam photon radia-
tion therapy2, 3 are based on the Dw mode, and the use of
either Dm or Dw (after the conversion of Dm to Dw) for
MC-based photon dose calculations remains a debating top-
ic.4
Varian's Eclipse TPS (Varian Medical Systems, Palo Alto,
CA) has implemented Acuros XB (AXB) dose calculation
algorithm, which can report the absorbed dose in both the
Dm and Dw options. The AXB utilizes the Linear Boltzmann
Transport Equation (LBTE) and solves numerically that de-
scribes the macroscopic behavior of ionizing particles as they
travel through and interact with matter.5 For the AXB_Dm,
the macroscopic energy deposition cross-section and atomic
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density are based on the material properties of local voxel,
whereas for the AXB_Dw, the energy deposition
cross-sections are used for the local media.5−7 Detail descrip-
tions on AXB can be found in the published literature.5−7
Several investigators5−31 have studied the dosimetric impact
of AXB using Dm reporting mode, and compared the
AXB_Dm results with MC simulations, measurements, and
Anisotropic Analytical Algorithm (AAA) calculations. Few
studies have reported the difference between the Dm and Dw
in AXB using MC simulations23, measurements24, 25, 26, and
computed tomography (CT) data of real patients for naso-
pharygeal carcinoma26 (planning technique used: intensity
modulated radiation therapy (IMRT)), and soft-tissue sar-
coma27 (planning technique used: volumetric modulated arc
therapy (VMAT)). Literature review shows that studies
comparing AXB_Dm and AXB_Dw calculations on real clini-
cal cases are limited. Hence, it is essential to further investi-
gate if the selection of either Dm or Dw in AXB will make a
significant dosimetric impact in the clinical environment.
The major purpose of this study was to compare the dosi-
metric results of the AXB_Dm calculations with that of
AXB_Dw calculations on real patient treatment plans for the
prostate, lung, and breast cancer.
Methods and Materials
Patient selection and CT simulation
In this retrospective study, all dosimetric data were obtained
from 21st Century Oncology, Naples, Florida, USA. The pa-
tient selection was done based on the localizations of the
tumor, which included prostate cancer (Group 1), stereotac-
tic body radiation therapy (SBRT) lung cancer (Group 2),
right breast cancer (Group 3), and left breast cancer (Group
4). Each group consisted five cases previously treated with
external beam photon radiation therapy at 21st Century On-
cology, Naples, Florida, USA. All patients underwent stand-
ard CT simulation on a Phillips Brilliance CT Scanner. The
CT scans were acquired using 512 × 512 pixels and 2.5 mm
slice thickness. After the CT simulation, DICOM CT images
were transferred to the Eclipse TPS for contouring and plan-
ning purpose.
Contouring
All four groups of patients included the planning target
volume (PTV), which was expanded from the clinical target
volume (CTV) drawn by the physician. Additionally, organs
at risk (OARs) were delineated based on the axial CT images.
The OARs of each group of patients are provided in Table 1.
Treatment planning
Treatment plans of all four groups of patients were generated
in the Eclipse TPS (version 11.2) using RapidArc, IMRT, and
3D conformal radiation therapy (3DCRT) (Energy: 6 MV
X-ray; Machine: TrueBeam (Varian Medical Systems, Palo
Alto, CA, USA)). For prostate cases, the total dose prescribed
to the PTV was 81 Gy with a daily dose of 1.8 Gy in 45 frac-
tions. The prostate cancer treatment plans were generated
using a single-full-arc. For the SBRT lung cases, the total
dose prescribed to the PTV was 50 ‒ 60 Gy with a daily dose
of 10 or 12 Gy in 5 fractions. The SBRT lung cancer treat-
ment plans were generated using 5-field IMRT (n = 4) and
2-partial-arc RapidArc (n = 1) techniques.
For the right breast cancer cases, the total dose prescribed to
the PTV was 45 Gy (n = 4) and 46.8 Gy (n = 1) with a daily
dose of 1.8 Gy. The treatment plans were generated using
2-tangent fields IMRT (n = 4) and 2-tangent fields 3DCRT (n
= 1) techniques. For all 5 left breast cancer cases, the total
dose prescribed to the PTV was 45 Gy with a daily dose of
1.8 Gy in 25 fractions. The treatment plans were generated
using 2-tangent fields IMRT (n = 3) and 2-partial-arc Rapi-
dArc (n = 2) techniques. The isocenter in all treatment plans
was placed at the center of the PTV.
The treatment plans of all four groups of patients were opti-
mized using the Varian Eclipse Progressive Resolution Op-
timizer (version 11.2) with an objective of meeting the plan-
ning objectives of institutional guidelines. After the optimi-
zation process, each treatment plan was calculated using
AXB_Dm (version 11.2) and AXB_Dw (version 11.2). The dose
calculation grid size was set to 2 mm for all the cases. The
calculated treatment plans were normalized such that the
prescribed dose covered at least 95% of the PTV.










Rectum Ipsi-Lung Contra-Breast Contra-Breast
Bladder Contra-Lung Ipsi-Lung Ipsi-Lung
Femoral Heads Heart Contra-Lung Contra-Lung
Spinal Cord Heart Heart
Skin Skin
Abbreviations: Ipsi = Ipsi-lateral; Contra = Contra-lateral; SBRT = Stereotactic Body Radiation Therapy
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Plan evaluation
The dose-volume histograms (DVHs) of both the AXB_Dm
and AXB_Dw were generated in the Eclipse TPS. Treatment
plans were evaluated for various dosimetric parameters. For
a comparative purpose, the relative difference (∆) in the cor-
responding dosimetric parameter (for example, mean dose,
maximum dose, etc.) between the AXB_Dm and AXB_Dw
plans of the same case was calculated using Equation 1.
_ ( ) _ ( ) ( ) = 100 ---------(1)_ ( )
w m
w
AXB D x AXB D xx AXB D x
 
where, x is the corresponding dosimetric parameter in the
AXB_Dw and AXB_Dm plans of the same case.
Results
The dosimetric results in the AXB_Dm and AXB_Dw plans of
all four groups of patients are presented in Figures 1-4.
Prostate cancer
For the prostate cancer, in comparison to the AXB_Dm plans,
the AXB_Dw plans produced a higher mean dose to the PTV
(∆avg=0.8%), rectum (∆avg=0.4%), bladder (∆avg=1.4%), and
femoral heads (∆ avg=2.5%). The relative rectal volume ex-
posed to radiation was higher in the AXB_Dw plans with the
average relative differences of 0.6% for V30, 0.9% for V50, and
1.3% for V70. Similarly, the relative bladder volume exposed
to radiation was higher in the AXB_Dw plans with the aver-
age relative differences of 1.4% for V30, 2.3% for V50, and
4.5% for V70.
SBRT lung cancer
For SBRT lung cancer, the mean dose in the AXB_Dw plans
was consistently higher for the heart (∆avg=1.3%) and esoph-
agus (∆ avg=0.7%) but almost identical for the PTV
(∆ avg=-0.1%). In evaluating the mean dose to the ipsi-lung
and contra-lung, no clear trend was observed, with AXB_Dw
plans producing higher values in 2 cases for the ipsi-lung and
in 3 cases for the contra-lung. For the ipsi-lung, the V5, V10,
and V20 were similar in the AXB_Dw and AXB_Dm, with an
average relative difference within ±0.4%. For the V5 of the
contra-lung, the averaged difference is -0.2% (range, -1.3%
to 0.1%) with higher values in the AXB_Dwplans in 3 cases.
The maximum dose to the spinal cord was consistently high-
er (∆ avg=2.1%) in the AXB_Dw plans, with a relative differ-
ence ranged from 1.4% to 4.4%.
FIG. 1: Relative difference (∆) in dosimetric results between the AXB_Dw and AXB_Dm plans for 5 different prostate cancer cases. Vn means
percentage volume irradiated by n Gy or more of a certain structure. The ∆ is defined in Equation 1.
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FIG. 2: Relative difference (∆) in dosimetric results between the AXB_Dw and AXB_Dm plans for 5 different SBRT lung cases. Vn means per-
centage volume irradiated by n Gy or more of a certain structure. The ∆ is defined in Equation 1.
FIG. 3: Relative difference (∆) in dosimetric results between the AXB_Dw and AXB_Dm plans for 5 different left breast cancer cases. Vn means
percentage volume irradiated by n Gy or more of a certain structure. The ∆ is defined in Equation 1.
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FIG. 4: Relative difference (∆) in dosimetric results between the AXB_D w and AXB_Dm plans for 5 different right breast cancer cases. Vn means
percentage volume irradiated by n Gy or more of a certain structure. The ∆ is defined in Equation 1.
Left breast cancer
For the left breast cancer, the difference in the PTV maxi-
mum dose between the AXB_Dw and AXB_Dm plans ranged
from -0.4% to -0.9%. On average, the mean dose in the
AXB_Dw plans was higher for the ipsi-lung (∆avg=0.7%), con-
tra-lung (∆ avg=0.6%), and heart (∆avg=2.6%), whereas
AXB_Dm plans had higher values for the maximum dose to
the skin (∆avg=-0.9%) and contra-breast (∆avg=-0.6%). For the
ipsi-lung, the AXB_Dw plans had higher values in the case of
V5 (∆avg=1.5%) and V20 (∆avg=1.2%).
Right breast cancer
For the right breast cancer, the difference in the PTV maxi-
mum dose between the AXB_Dw and AXB_Dm plans ranged
from -0.3% to -1.5%. The mean dose in the AXB_Dw plans
was higher for the ipsi-lung (∆ avg=1.2%) and almost identical
for the majority of the cases for the contra-lung and heart
(except for case #2 and #5). On average, the AXB_Dm plans
had higher values for the maximum dose to the skin
(∆avg=-0.3%) and contra-breast (∆avg=-0.9%). In the case of
ipsi-lung, on average, the AXB_Dw plans had higher values
for the V5 (∆avg=1.2%) and V20 (∆ avg=0.8%) when compared to
the AXB_Dm plans.
Discussion
The dosimetric impact of Dm and Dw reporting mode in AXB
was investigated for the prostate, SBRT lung, and breast
cancer. The AXB_Dm and AXB_Dw plans were evaluated
based on the results derived from the DVH in the Eclipse
TPS. The preliminary results from the clinical cases in this
study showed that the differences in dosimetric results be-
tween the AXB_Dm and AXB_Dw plans depend on the tumor
type. For instance, the mean PTV dose in the AXB_Dw plans
was slightly higher (relative difference up to 1.0%) for the
prostate cancer when compared to the mean PTV dose in the
AXB_Dw plans for the SBRT lung cancer (relative difference
within ±0.3%). Kan et al.26 and Fogliata et al.27 also reported
higher values calculated by AXB_Dw when compared to the
ones calculated by AXB_Dm.
The analysis of the OAR results for the prostate cancer (Fig-
ure 1) showed that the AXB_Dw plans consistently produced
higher values for the bladder and femoral heads but not for
the rectum. In the case of SBRT lung (Figure 2), a clear trend
was seen for the heart mean dose and spinal cord maximum
dose, with AXB_Dw plans producing higher values when
compared to the AXB_Dm plans. However, the difference in
the lung doses between the AXB_Dm and AXB_Dw plans did
not always produce a clear trend, with the relative difference
ranged from -1.4% to 2.9%. For both the left and right breast
cancer, we observed higher maximum dose to the PTV as
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well as higher mean dose to the heart in the AXB_Dm plans,
and this was true for all cases. The evaluation of the maxi-
mum dose to the skin showed higher values in the AXB_Dm
plans for all 5 left breast cancer cases, whereas only 2 cases
had higher maximum dose to the skin in the AXB_Dm plans
for the right breast cancer cases.
The results presented in this study demonstrated that the
difference between the AXB_Dm and AXB_Dw calculations is
dependent on the tumor type, and even for the same type of
tumor, the results are patient specific. The use of Dm vs. Dw
for external beam photon radiation therapy is an interesting
debating topic for the medical physics community.4 On one
hand, the supporters of Dm reason that (i) conversion from
Dm to Dw adds uncertainty in dose calculations due to uncer-
tainties in computed stopping power ratios; (ii) changing to
Dm will have minimal impact on the treatment protocols;
(iii) Dm is more likely to provide a better measure of biologi-
cal response; and (iv) conversion of the Dm to Dw defeats a
potential advantage of using MC-based dose calculation algo-
rithms. On the other hand, the supporters of Dw argue that
(i) commissioning beam data are always measured in water;
(ii) clinical experience in terms of tumor/tissue response is
based on Dw; (iii) dosimetry calibration protocols are based in
water; and (iv) conversion from CT numbers to media results
uncertainty in the medium type and composition.
Conclusion
The preliminary dosimetric results from our clinical study
showed that the selection of either Dm or Dw in AXB is less
likely to produce significant dosimetric differences in the
clinical environment. However, the difference between the
AXB_Dm and AXB_Dw calculations depends on the disease
site, and even for the same type of disease (e.g., lung cancer),
the results are patient specific. Future studies need to include
large cohort of clinical cases with different types of cancer.
Also, it is recommended to investigate the dosimetric impact
of the treatment technique (e.g., 3DCRT, IMRT, and VMAT)
on the AXB_Dm and AXB_Dw calculations for different types
of cancer.
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